Clinical Trial Update: Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating topical ruxolitinib in chronic hand eczema has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hand Eczema

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Chronic Hand Eczema (CHE) | Phase 3 | Status: WITHDRAWN